Article Versions Notes

Agbarya A, Sarel I, Ziv-Baran T, Schwartz O, Shechtman Y, Kozlener E, Khoury R, Sheikh-Ahmad M, Saiegh L, Swaid F, et al. Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments. Diseases. 2023; 11(4):128. https://doi.org/10.3390/diseases11040128

Agbarya, Abed, Ina Sarel, Tomer Ziv-Baran, Orna Schwartz, Yelena Shechtman, Ella Kozlener, Rasha Khoury, Mohammad Sheikh-Ahmad, Leonard Saiegh, Forat Swaid, and et al. 2023. "Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments" Diseases 11, no. 4: 128. https://doi.org/10.3390/diseases11040128

Agbarya, A., Sarel, I., Ziv-Baran, T., Schwartz, O., Shechtman, Y., Kozlener, E., Khoury, R., Sheikh-Ahmad, M., Saiegh, L., Swaid, F., Ahmad, A. A., Janzic, U., & Brenner, R. (2023). Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments. Diseases, 11(4), 128. https://doi.org/10.3390/diseases11040128